当前位置: 首页 > 详情页

Panax notoginseng saponins provide neuroprotection by regulating NgR1/RhoA/ROCK2 pathway expression, in vitro and in vivo

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med Educ Minist & Beijin, Beijing, Peoples R China; [2]Beijing Univ Chinese Med, Affiliated Hosp 3, Dept Pediat, Beijing, Peoples R China; [3]Capital Med Univ, Beijing Childrens Hosp, Dept Rehabil, Beijing, Peoples R China
出处:
ISSN:

关键词: Panax notoginseng saponins Cerebral infarction NEP1-40 NgR1 RhoA ROCK2

摘要:
Ethnopharmacological relevance: Panax notoginseng saponins (PNS) extracted from a traditional Chinese herbal medicine, Panax notoginseng (Burkill) F.H. Chen (Araliaceae), which has been extensively used in treating coronary heart disease, ischemic cerebrovascular disease and hemorrhagic disorders in China over hundreds of years. Aims of the study: This study explored whether panax notoginseng saponins (PNS) provided neuroprotective effects by inhibiting the expressions of NgR1, RhoA, and ROCK2 following middle cerebral artery occlusion in rats and oxygen-glucose deprivation/reoxygenation (OGD/R) injury in SH-SY5Y cells. Materials and methods: 2,3,5-Triphenyltetrazolium chloride staining was used to determine successful middle cerebral artery occlusion establishment in sham-operated and operated Sprague-Dawley rats 1 day after injury. The rats were randomly separated into sham, model, NEP1-40, PNS, and NEP1-40 plus PNS (N+P) groups. After 7 days of treatment, body mass and neurological deficit scores were analyzed. Tissues were harvested and analyzed by hematoxylin-eosin staining and immunohistochemical analysis, western blotting, and quantitative real-time PCR (qRT-PCR). The optimal drug concentration of NEP1-40 and PNS on SH-SY5Y cells exposed to OGD/R injury was determined by CCK8 analysis. qRT-PCR was used to measure mRNA expression profiles of NgR1, RhoA, and ROCK2 in SH-SY5Y cells subjected to OGD/R. Results: The results showed that MCAO surgery successfully produced an infarct, and the PNS, NEP1-40, and N+P groups exhibited increased body mass and ameliorated neurological deficits compared with the model group. NEP1-40 treatment markedly reduced NgR1 and RhoA overexpression when compared to the model group, although there was no significant difference in ROCK2 expression. PNS and N+P treatment significantly decreased NgR1, RhoA, and ROCK2 overexpression compared with the model group. However, N+P treatment did not result in a synergistic effect, as assessed by immunohistochemistry, western blotting, and qRT-PCR. Following optimal administration of PNS (160 mu g/ml) and NEP1-40 (10 ng/m1) on SH-SY5Y cells exposed to OGD/R injury, cell viability in the NEP1-40, PNS, and N+P groups significantly increased compared with the model group, as assessed by CCK8 analysis. Additionally, NgR1, RhoA, and ROCK2 mRNA expression profiles were significantly less in the NEP1-40, PNS, and N+P groups compared with the model group. Conclusion: PNS provided neuroprotective effects in a rat model of cerebral ischemia and SH-SY5Y cells exposed to oxygen/glucose deprivation injury by inhibiting the overexpression of NgR1, RhoA, and ROCK2. (C) 2016 Published by Elsevier Ireland Ltd.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 3 区 医学
小类 | 2 区 全科医学与补充医学 3 区 药物化学 3 区 药学 3 区 植物科学
最新[2023]版:
大类 | 2 区 医学
小类 | 1 区 药物化学 1 区 全科医学与补充医学 1 区 药学 1 区 植物科学
JCR分区:
出版当年[2014]版:
Q1 PLANT SCIENCES Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q2 CHEMISTRY, MEDICINAL Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q1 CHEMISTRY, MEDICINAL Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PLANT SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med Educ Minist & Beijin, Beijing, Peoples R China;
通讯作者:
通讯机构: [1]Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med Educ Minist & Beijin, Beijing, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院